Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH OTCMKTS:CXRXF NASDAQ:DYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.59-0.2%$19.24$16.65▼$31.26$865.54M0.89428,035 shs620,356 shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsDYNDyne Therapeutics$23.83+1.6%$20.03$8.88▼$25.00$3.88B1.062.12 million shs1.35 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-0.20%+4.15%+4.15%-6.67%-7.55%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%DYNDyne Therapeutics+1.62%+0.21%+20.35%+21.15%+159.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.59-0.2%$19.24$16.65▼$31.26$865.54M0.89428,035 shs620,356 shsCXRXFADVANZ PHARMA$17.06$17.06$2.13▼$18.00$834.46MN/A11,851 shs39 shsDYNDyne Therapeutics$23.83+1.6%$20.03$8.88▼$25.00$3.88B1.062.12 million shs1.35 million shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-0.20%+4.15%+4.15%-6.67%-7.55%CXRXFADVANZ PHARMA0.00%0.00%0.00%0.00%0.00%DYNDyne Therapeutics+1.62%+0.21%+20.35%+21.15%+159.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.63Reduce$22.0012.30% UpsideCXRXFADVANZ PHARMA 0.00N/AN/AN/ADYNDyne Therapeutics 2.86Moderate Buy$34.1743.38% UpsideCurrent Analyst Ratings BreakdownLatest DYN, AMPH, and CXRXF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026DYNDyne Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)6/29/2026AMPHAmphastar Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$25.00 ➝ $20.006/26/2026DYNDyne Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/22/2026AMPHAmphastar Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/3/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$23.00 ➝ $20.005/15/2026DYNDyne Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/13/2026DYNDyne Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$23.00 ➝ $24.005/11/2026AMPHAmphastar Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$25.00 ➝ $21.005/8/2026AMPHAmphastar Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.20$4.25 per share4.61$17.17 per share1.14CXRXFADVANZ PHARMA$525.58M1.59N/AN/A$0.16 per share106.63DYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6611.806.693.8611.00%15.12%7.14%8/6/2026 (Estimated)CXRXFADVANZ PHARMA-$74.86MN/AN/AN/AN/A-15.31%N/A-4.38%N/ADYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)Latest DYN, AMPH, and CXRXF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AMPHAmphastar Pharmaceuticals$0.63N/AN/AN/A$179.71 millionN/A7/27/2026Q2 2026DYNDyne Therapeutics-$0.74N/AN/AN/AN/AN/A5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ACXRXFADVANZ PHARMAN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82CXRXFADVANZ PHARMA257.042.391.61DYNDyne Therapeutics0.1719.9219.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%CXRXFADVANZ PHARMAN/ADYNDyne Therapeutics96.68%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%CXRXFADVANZ PHARMAN/ADYNDyne Therapeutics9.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableCXRXFADVANZ PHARMA42948.91 millionN/ANot OptionableDYNDyne Therapeutics100165.31 million149.68 millionOptionableDYN, AMPH, and CXRXF HeadlinesRecent News About These CompaniesDyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common StockJuly 21 at 10:46 PM | globenewswire.comDyne Therapeutics launches $300M stock offering; shares fall 14% in after hoursJuly 21 at 8:01 PM | msn.comDyne Therapeutics Announces $300 Million Proposed Public Offering of Common StockJuly 21 at 4:51 PM | quiverquant.comQDyne Therapeutics Announces Proposed Public Offering of Common StockJuly 21 at 4:46 PM | globenewswire.comDYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?July 21 at 11:20 AM | zacks.comDyne Therapeutics trades sideways over an FDA hurdle. Is it time to take profits?July 20 at 11:19 PM | msn.comFDA accepts Dyne Duchenne BLA, grants Priority ReviewJuly 20 at 6:19 PM | thepharmaletter.comTDyne Therapeutics: A Buy, With Caveats, On DMD ProgressJuly 20 at 3:00 PM | seekingalpha.comDyne Therapeutics Advances DYNE-251 With FDA Priority ReviewJuly 20 at 8:30 AM | tipranks.comDyne Therapeutics’ z-rostudirsen Accepted for FDA Review with Priority Review Granted for Duchenne Muscular Dystrophy July 20 at 7:51 AM | quiverquant.comQDyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)July 20 at 7:30 AM | globenewswire.comDyne Therapeutics (DYN) to Release Earnings on MondayJuly 20 at 3:26 AM | americanbankingnews.comDyne Therapeutics (DYN) Expected to Announce Earnings on MondayJuly 20 at 3:25 AM | marketbeat.comDyne Therapeutics (DYN) Inspires Confidence With Its Force PlatformJuly 16, 2026 | finance.yahoo.comY Intercept Hong Kong Ltd Cuts Stock Holdings in Dyne Therapeutics, Inc. $DYNJuly 12, 2026 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 297,211 Shares of StockJuly 9, 2026 | insidertrades.comDyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 297,211 SharesJuly 8, 2026 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Director Sells 480,240 Shares of StockJuly 8, 2026 | marketbeat.comGuggenheim Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)July 8, 2026 | theglobeandmail.comDyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?July 4, 2026 | fool.comSG Americas Securities LLC Sells 152,758 Shares of Dyne Therapeutics, Inc. $DYNJuly 2, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The AI Boom Has a Second Act—And It's Playing Out in OpticsBy Bridget Bennett | June 29, 2026These 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialBy Nathan Reiff | July 8, 2026Prepare for the Next Wave of Factory Automation With These 3 Standout NamesBy Nathan Reiff | July 14, 2026DYN, AMPH, and CXRXF Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$19.59 -0.04 (-0.20%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$19.60 +0.00 (+0.03%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.ADVANZ PHARMA OTCMKTS:CXRXF$17.06 0.00 (0.00%) As of 06/10/2021ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Dyne Therapeutics NASDAQ:DYN$23.83 +0.38 (+1.62%) Closing price 07/21/2026 04:00 PM EasternExtended Trading$21.22 -2.61 (-10.94%) As of 04:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings 3 Photonics Companies Making Quantum Tech Possible Confidence Is Back, But Earnings Show the Consumer Is Being Picky Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
